are presenting for cataract surgery. We continue to see evolution and
new products in this area.
Within the past year, the FDA has approved 2 MIGS stents that go
into Schlemm's canal, the drainage system of the eye, and expand
its width. As a result, these canal-based trabecular microbypass
stents — Ivantis's Hydrus Microstent and Glaukos's iStent inject —
improve the outflow of aqueous fluid in order to reduce IOP, sup-
plementing the IOP relief provided by the concurrent cataract sur-
gery. After the stent is implanted, I monitor the patient's IOP to
make sure it's working properly.
The first generation of the iStent works well, but has a steep learning
curve and can be technically challenging to insert. Getting the right
angle and depth of insertion can be difficult. With the second genera-
tion, iStent Inject, you
implant 2 devices,
potentially getting
more IOP lowering. I
have found them easi-
er to insert as well.
A U G U S T 2 0 1 9 • O U T PA T I E N T S U R G E R Y. N E T • 9 5
www.viscot.com
viscotcs@viscot.com • 800.221.0658
Cataract site marking solution
• Sufficiently permanent to
resist prep
• Easily removed post
procedure
• Visible on all patient skin tones
Quick to apply, easy to
remove - see demo:
w w w.bit.ly/tatmarker
temporary skin indicia
